JP2024527288A5 - - Google Patents
Info
- Publication number
- JP2024527288A5 JP2024527288A5 JP2023579158A JP2023579158A JP2024527288A5 JP 2024527288 A5 JP2024527288 A5 JP 2024527288A5 JP 2023579158 A JP2023579158 A JP 2023579158A JP 2023579158 A JP2023579158 A JP 2023579158A JP 2024527288 A5 JP2024527288 A5 JP 2024527288A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/102324 | 2021-06-25 | ||
| CNPCT/CN2021/102324 | 2021-06-25 | ||
| CNPCT/CN2022/092803 | 2022-05-13 | ||
| CNPCT/CN2022/092803 | 2022-05-13 | ||
| PCT/CN2022/101000 WO2022268192A1 (en) | 2021-06-25 | 2022-06-24 | Anti-ccr8 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024527288A JP2024527288A (ja) | 2024-07-24 |
| JP2024527288A5 true JP2024527288A5 (https=) | 2025-07-02 |
| JPWO2022268192A5 JPWO2022268192A5 (https=) | 2025-07-02 |
Family
ID=84544143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579158A Pending JP2024527288A (ja) | 2021-06-25 | 2022-06-24 | 抗ｃｃｒ８抗体及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240352134A1 (https=) |
| EP (1) | EP4359442A4 (https=) |
| JP (1) | JP2024527288A (https=) |
| KR (1) | KR20240025013A (https=) |
| CN (1) | CN117616046A (https=) |
| AU (1) | AU2022298850A1 (https=) |
| TW (1) | TW202325732A (https=) |
| WO (1) | WO2022268192A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| CN117285627B (zh) * | 2023-09-06 | 2024-06-14 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
| AR134514A1 (es) | 2023-12-01 | 2026-01-21 | Gilead Sciences Inc | Proteína de fusión anti-fap-ligera y uso de esta |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| CN119080936B (zh) * | 2024-10-24 | 2025-05-23 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| CN110835371A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8单克隆抗体及其应用 |
| CN113260381A (zh) * | 2018-12-27 | 2021-08-13 | 盐野义制药株式会社 | 新型抗ccr8抗体 |
| US20230119066A1 (en) * | 2020-03-23 | 2023-04-20 | Bristol-Myers Squibb Company | Anti-ccr8 antibodies for treating cancer |
-
2022
- 2022-06-24 TW TW111123764A patent/TW202325732A/zh unknown
- 2022-06-24 JP JP2023579158A patent/JP2024527288A/ja active Pending
- 2022-06-24 AU AU2022298850A patent/AU2022298850A1/en active Pending
- 2022-06-24 US US18/573,978 patent/US20240352134A1/en active Pending
- 2022-06-24 CN CN202280044035.8A patent/CN117616046A/zh active Pending
- 2022-06-24 KR KR1020247003056A patent/KR20240025013A/ko active Pending
- 2022-06-24 EP EP22827684.6A patent/EP4359442A4/en active Pending
- 2022-06-24 WO PCT/CN2022/101000 patent/WO2022268192A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024527288A5 (https=) | ||
| CL2025003837A1 (es) | Anticuerpo monoclonal o fragmento unión a antígeno del mismo que se une específicamente a axl | |
| CL2025003367A1 (es) | Nanosupensiones de corticosteroides y sus usos | |
| BR102023014872A2 (https=) | ||
| BR102023012440A2 (https=) | ||
| BR102023010976A2 (https=) | ||
| BR202022009269U2 (https=) | ||
| BR202022005961U2 (https=) | ||
| BR202022001779U2 (https=) | ||
| BR202022000931U2 (https=) | ||
| BY13156U (https=) | ||
| BY13150U (https=) | ||
| BY13168U (https=) | ||
| CN307047671S (https=) | ||
| CN307046860S (https=) | ||
| BY13167U (https=) | ||
| BY13166U (https=) | ||
| BY13165U (https=) | ||
| BY13164U (https=) | ||
| BY13163U (https=) | ||
| BY13161U (https=) | ||
| BY13160U (https=) | ||
| BY13158U (https=) | ||
| BY13157U (https=) | ||
| CN307048102S (https=) |